# 4,5-diethyl-3'-ethoxy-pyroflavone **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/45-diethyl-3-ethoxy-pyroflavone **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-03 **Evidence Score:** 1 / 10 **Category:** Compound **Also Known As:** 4,5-diethyl-3'-ethoxypyroflavone, diethyl ethoxy pyroflavone, pyroflavone antifilarial derivative, ethoxypyroflavone ## Overview 4,5-diethyl-3'-ethoxy-pyroflavone is a pyroflavone-class flavonoid derivative characterized by ethyl substitutions at the C-4 and C-5 positions and an ethoxy group at the 3'-position of the B-ring, structural features that are hypothesized to confer antifilarial activity through mechanisms common to flavonoid bioactives such as interference with parasite metabolic enzymes or membrane integrity. Its reported antifilarial effect is dose-dependent, but quantitative efficacy data, effect sizes, and validated clinical or preclinical study results have not been published in the accessible scientific literature as of the current review. ## Health Benefits - **Antifilarial Activity (Dose-Dependent)**: This compound has been referenced alongside antifilarial natural product investigations, with dose-dependent activity implied; however, no published in vitro IC50 values, in vivo parasite burden reductions, or mechanistic confirmation studies are available in the indexed literature to substantiate the magnitude of this effect. - **Flavonoid-Class Antioxidant Potential**: As a structural member of the flavone family, 4,5-diethyl-3'-ethoxy-pyroflavone theoretically carries antioxidant capacity through resonance stabilization of [free radical](/ingredients/condition/antioxidant)s via its aromatic hydroxyl and ether substituents, a property well-documented across the broader flavonoid class but not yet measured for this specific compound. - **Putative [Anti-inflammatory](/ingredients/condition/inflammation) Properties**: Flavone derivatives with B-ring alkoxy substitutions have been shown in related analogs to inhibit cyclooxygenase (COX) and lipoxygenase (LOX) enzymes; by structural analogy, this compound may share these properties, though direct experimental confirmation is absent. - **Potential Antiparasitic Spectrum**: The pyroflavone scaffold has been explored in neglected tropical disease research for activity against filarial nematodes such as Wuchereria bancrofti and Brugia malayi; the ethoxy and diethyl substitutions may modulate membrane permeability or enzyme inhibition in parasite cells, but this remains speculative without confirmatory data. - **Hypothesized Enzyme Inhibition**: Structurally similar flavonoids inhibit parasite-specific enzymes including thymidylate kinase and [glutathione](/ingredients/condition/detox) reductase; whether the diethyl and ethoxy modifications on this compound enhance selectivity for parasite versus host enzymes is an open research question with no published answer. ## Mechanism of Action Based on structural analogy to characterized pyroflavone and flavone derivatives, 4,5-diethyl-3'-ethoxy-pyroflavone is hypothesized to exert antifilarial activity through disruption of [energy metabolism](/ingredients/condition/energy) in filarial nematodes, potentially by inhibiting mitochondrial electron transport chain complexes or interfering with [acetylcholine](/ingredients/condition/cognitive)sterase function that governs neuromuscular activity in parasitic worms. The ethyl substituents at C-4 and C-5 increase lipophilicity relative to unsubstituted flavones, potentially enhancing membrane penetration into the cuticle of microfilariae and adult worms. The 3'-ethoxy group on the B-ring may modulate binding affinity to parasite-specific cytochrome P450 enzymes or thioredoxin reductase, enzymes critical to redox homeostasis in helminths. However, these mechanistic proposals are entirely inferential from analogs; no receptor binding assays, enzyme inhibition kinetics, or molecular docking studies for this specific compound appear in the published literature. ## Clinical Summary No clinical trials—neither Phase I safety studies, Phase II dose-finding studies, nor Phase III efficacy trials—have been identified for 4,5-diethyl-3'-ethoxy-pyroflavone in human or animal models. The compound's designation as antifilarial 'in a dose-dependent manner' appears to derive from its inclusion in a natural product review without citation of primary experimental data, precluding any assessment of effect size, therapeutic window, or patient population relevance. Without pharmacokinetic data (absorption, distribution, [metabolism](/ingredients/condition/weight-management), excretion), it is not possible to determine bioavailability, appropriate dosing intervals, or tissue distribution relevant to filarial infections typically located in the lymphatic system. Confidence in any clinical utility is therefore negligible pending generation of foundational preclinical data. ## Nutritional Profile 4,5-diethyl-3'-ethoxy-pyroflavone is not a nutritional ingredient and contributes no established macronutrient, micronutrient, or dietary fiber content. As a synthetic or isolated flavone-class compound, it functions as a phytochemical rather than a nutritive substance; its molecular formula (derived from pyroflavone with diethyl and ethoxy modifications) places it in the polyphenol category structurally but without measured [antioxidant](/ingredients/condition/antioxidant) capacity values (e.g., ORAC, FRAP, DPPH assay results) specific to this compound. No bioavailability data—including oral absorption fraction, plasma half-life, protein binding, or tissue distribution coefficients—have been published, making nutritional or pharmacokinetic profiling impossible at this time. ## Dosage & Preparation - **Research-Grade Powder**: No established human dose exists; the compound has not advanced to clinical dosage determination and is available only as a chemical standard for research purposes. - **Theoretical Oral Administration**: By analogy to related antifilarial flavonoids investigated preclinically, oral routes would be the primary delivery hypothesis, but no formulation studies (solubility enhancement, nanoparticle encapsulation, lipid-based delivery) have been published for this compound. - **Standardization**: No standardization percentage or extract specification has been established, as no plant source or extraction protocol has been confirmed in the literature. - **Effective Dose Range**: Entirely undetermined; no LD50, NOAEL, LOAEL, or therapeutic dose has been reported in preclinical or clinical settings. - **Timing and Frequency**: Not established; the dose-dependent antifilarial claim referenced in the literature does not include frequency, duration, or timing parameters. ## Safety & Drug Interactions The safety profile of 4,5-diethyl-3'-ethoxy-pyroflavone is entirely unknown; no toxicological studies, adverse event reports, maximum tolerated dose determinations, or safety pharmacology assessments have been published for this compound in humans or animals. No drug interaction data exist; however, given its flavone scaffold, theoretical interactions with CYP450 enzymes (particularly CYP3A4 and CYP1A2, which are modulated by multiple flavonoids) cannot be excluded, suggesting caution if co-administered with narrow therapeutic index drugs such as warfarin, cyclosporine, or antiretrovirals. Use during pregnancy or lactation is contraindicated by default given the complete absence of reproductive toxicity data, consistent with standard precautionary principles applied to uncharacterized synthetic compounds. This compound should not be used in any human context outside of strictly controlled, ethically approved research settings until foundational toxicological characterization is completed. ## Scientific Research The scientific evidence base for 4,5-diethyl-3'-ethoxy-pyroflavone is critically sparse: it appears in the accessible literature only as a named compound within a broader review of natural products investigated for tropical infectious diseases, with no accompanying pharmacological data, study design descriptions, or quantified outcomes. No primary research articles, preclinical in vitro or in vivo studies, pharmacokinetic analyses, or clinical trials involving this compound could be identified through systematic search of PubChem, standard biomedical databases, or the provided search results. Structural analogs within PubChem confirm the compound's chemical plausibility but provide no biological activity data. Given this evidentiary vacuum, any pharmacological claims must be considered entirely preliminary and speculative; independent targeted research using chemical databases, patent literature, and direct experimental work would be required before any evidence-based claims can be made. ## Historical & Cultural Context No traditional medicine system—including Ayurveda, Traditional Chinese Medicine, Unani, or African ethnopharmacology—has been documented as using 4,5-diethyl-3'-ethoxy-pyroflavone by name or as an isolated compound, which is consistent with its apparent identity as a synthetic or semi-synthetic derivative rather than a whole-plant remedy. Its tangential association with Vitex negundo in a tropical disease review suggests it may have been identified during phytochemical fractionation or synthetic analog programs inspired by that plant's documented ethnobotanical use against inflammatory and parasitic conditions across South and Southeast Asia. Vitex negundo itself carries centuries of documented use in Ayurvedic and folk medicine for fever, [inflammation](/ingredients/condition/inflammation), and skin conditions, but the specific pyroflavone derivative in question has no independently documented traditional history. Cultural or historical context is therefore inherited only indirectly through the broader flavonoid natural product lineage and cannot be specifically attributed to this compound. ## Synergistic Combinations No synergistic combinations have been studied or proposed for 4,5-diethyl-3'-ethoxy-pyroflavone in the published literature. By structural analogy to antifilarial flavonoids, combinations with diethylcarbamazine (DEC)—the standard-of-care antifilarial drug—or ivermectin have been explored for other plant-derived flavonoids and could represent a rational investigational direction if preclinical activity is confirmed. Similarly, co-administration with piperine, a known bioavailability enhancer for flavonoid-class compounds acting via CYP3A4 inhibition and P-glycoprotein modulation, represents a theoretical formulation strategy pending any primary efficacy data. ## Frequently Asked Questions ### What is 4,5-diethyl-3'-ethoxy-pyroflavone and what is it used for? 4,5-diethyl-3'-ethoxy-pyroflavone is a synthetic or semi-synthetic compound belonging to the pyroflavone subclass of flavonoids, characterized by ethyl groups at positions 4 and 5 and an ethoxy substituent at the 3'-position of its B-ring. It has been referenced in natural product literature in the context of antifilarial research—meaning activity against parasitic filarial worms—on a dose-dependent basis, but no confirmed pharmacological data, clinical trials, or validated mechanisms of action have been published for this specific compound. ### Is there scientific evidence supporting the antifilarial activity of 4,5-diethyl-3'-ethoxy-pyroflavone? The available scientific evidence is critically limited: the compound is mentioned in one broad review of natural products for tropical infectious diseases, but no primary research study, in vitro assay result, animal model outcome, or clinical trial has been published to substantiate or quantify its antifilarial activity. Its dose-dependent antifilarial designation cannot be verified against any published IC50, ED50, or parasite burden reduction data. Researchers interested in this compound would need to conduct foundational preclinical studies before any evidence-based conclusions can be drawn. ### What are the known side effects or safety concerns for 4,5-diethyl-3'-ethoxy-pyroflavone? No safety data, toxicological studies, or adverse event reports have been published for 4,5-diethyl-3'-ethoxy-pyroflavone in humans or animal models, meaning its side effect profile is entirely unknown. Standard precautionary principles for uncharacterized synthetic compounds apply: it should not be used outside controlled research settings, and its use in pregnancy or lactation is contraindicated by default. Theoretical drug interactions via CYP450 enzyme modulation—a known property of related flavonoids—cannot be ruled out. ### How does 4,5-diethyl-3'-ethoxy-pyroflavone differ from other antifilarial flavonoids? Compared to more extensively studied antifilarial flavonoids such as quercetin and kaempferol, 4,5-diethyl-3'-ethoxy-pyroflavone is distinguished by its diethyl substitutions at C-4 and C-5 and an ethoxy group at the B-ring 3'-position, modifications that increase lipophilicity and may alter binding to parasite-specific enzyme targets. While quercetin and kaempferol have published in vitro and in vivo antifilarial data against species such as Brugia malayi, 4,5-diethyl-3'-ethoxy-pyroflavone lacks any such published comparative or standalone pharmacological data, making direct comparison impossible at this time. ### What is the recommended dosage of 4,5-diethyl-3'-ethoxy-pyroflavone for antifilarial use? No recommended dosage has been established for 4,5-diethyl-3'-ethoxy-pyroflavone for any indication, including antifilarial use, because no dose-finding studies, pharmacokinetic analyses, or safety trials have been conducted or published. The compound has not been evaluated in any human clinical trial, and no preclinical dose-response data are publicly available to guide even investigational dosing protocols. Any use of this compound in humans outside a formally approved research study would be inappropriate given the complete absence of safety and efficacy data. ### What is the bioavailability of 4,5-diethyl-3'-ethoxy-pyroflavone and how does its chemical structure affect absorption? The bioavailability of 4,5-diethyl-3'-ethoxy-pyroflavone has not been formally characterized in human or animal studies, limiting understanding of how effectively the body absorbs this compound. The presence of ethoxy and diethyl substituents on the pyroflavone backbone may influence gastrointestinal permeability and hepatic metabolism, but no peer-reviewed absorption or pharmacokinetic data are currently available. Without established bioavailability data, it is unclear whether supplemental doses achieve therapeutically relevant systemic concentrations. ### Are there any known drug interactions between 4,5-diethyl-3'-ethoxy-pyroflavone and antiparasitic medications? No formal drug interaction studies have been conducted between 4,5-diethyl-3'-ethoxy-pyroflavone and conventional antiparasitic agents such as ivermectin or albendazole. As a flavonoid derivative, this compound may theoretically interact with cytochrome P450 enzymes involved in drug metabolism, but specific interaction data are absent from the indexed literature. Individuals taking prescription antiparasitic medications should consult a healthcare provider before using this ingredient to avoid potential additive or antagonistic effects. ### How does the research quality and evidence strength for 4,5-diethyl-3'-ethoxy-pyroflavone compare to established antifilarial drugs? The evidence base for 4,5-diethyl-3'-ethoxy-pyroflavone is significantly weaker than for FDA-approved antifilarials, as published studies lack quantified in vitro potency data (IC50 values), in vivo efficacy measures, or mechanistic validation in animal models. Established antifilarial medications have decades of clinical trial data and regulatory approval, whereas this compound remains in preliminary research stages with no human safety or efficacy trials documented. The gap between preliminary natural product screening and clinical-grade evidence substantially limits confidence in this ingredient's therapeutic utility. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*